TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

26 Dec 2024 11:21:56 By Nasdaq GlobeNewswire

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

23 Dec 2024 08:38:33 By Nasdaq GlobeNewswire

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

19 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

17 Dec 2024 12:32:20 By Nasdaq GlobeNewswire

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

10 Dec 2024 14:13:52 By Nasdaq GlobeNewswire

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

05 Dec 2024 10:03:20 By Nasdaq GlobeNewswire

Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy

26 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

21 Nov 2024 14:59:43 By Nasdaq GlobeNewswire

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

19 Nov 2024 15:50:42 By Nasdaq GlobeNewswire

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

14 Nov 2024 16:00:38 By Nasdaq GlobeNewswire

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

14 Nov 2024 14:49:39 By Nasdaq GlobeNewswire

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

08 Nov 2024 14:36:48 By Nasdaq GlobeNewswire

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

05 Nov 2024 15:43:31 By Nasdaq GlobeNewswire

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

05 Nov 2024 08:27:48 By Nasdaq GlobeNewswire

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

04 Nov 2024 13:36:34 By Nasdaq GlobeNewswire

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

31 Oct 2024 09:54:56 By Nasdaq GlobeNewswire

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

29 Oct 2024 14:28:32 By Nasdaq GlobeNewswire

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

29 Oct 2024 11:43:30 By Nasdaq GlobeNewswire

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

25 Oct 2024 16:34:17 By Nasdaq GlobeNewswire

Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

23 Oct 2024 07:35:00 By Nasdaq GlobeNewswire